Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmace...
NEPG: The net profit for the third quarter was 43.5245 million yuan, a decrease of 14.92%
NEPG: The holding subsidiary has obtained approval for drug clinical trials
NEPG: Chief Financial Officer Zhou Yana resigns due to health reasons
NEPG: Net profit of 129 million yuan in the first half of 2025, a year-on-year decrease of 17.62%
China Galaxy Securities: Cell gene therapy has entered the stage of result realization, and CXO is expected to benefit first
NEPG: The active pharmaceutical ingredient fosfomycin trometamol has received CEP certification